Download PDF
Thromb Haemost 2010; 103(04): 868-870
DOI: 10.1160/TH09-10-0709
Letters to the Editor
Schattauer GmbH

Long-term secondary prophylaxis with recombinant activated factor VII (rFVIIa) in haemophilia A with inhibitors: A case report

Peter Kubisz
1   Department of Hematology and Transfusiology, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine of the Comenius University, University Hospital, Martin, Slovakia
,
Ivana Plamenová
1   Department of Hematology and Transfusiology, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine of the Comenius University, University Hospital, Martin, Slovakia
,
Ján Staško
1   Department of Hematology and Transfusiology, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine of the Comenius University, University Hospital, Martin, Slovakia
,
Miroslava Dobrotová
1   Department of Hematology and Transfusiology, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine of the Comenius University, University Hospital, Martin, Slovakia
,
Pavol Hollý
1   Department of Hematology and Transfusiology, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine of the Comenius University, University Hospital, Martin, Slovakia
› Author Affiliations
Further Information

Publication History

Received: 19 October 2009

Accepted after minor revision: 04 February 2009

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Rodriguez-Merchan EC, Rocino A. Literature review of surgery management in inhibitor patients. Haemophilia 2004; 10 (Suppl. 02) 22-29.
    CrossrefPubMedGoogle Scholar
  • 2 Franchini M, Zaffanello M, Veneri D. Recombinant factor VIIa. An update on its clinical use. Thromb Haemost 2005; 93: 1027-1035.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Carlsson KS, Astermark J, Donfield S. et al. Cost and outcome: Comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor. Thromb Haemost 2008; 99: 1060-1067.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiency of factor VIII or IX with inhibitors. Haemophilia 2008; 14: 898-902.
    CrossrefPubMedGoogle Scholar
  • 5 Klitgaard T, Nielsen TG. Overview of the human pharmacokinetics of recombinant activated factor VII. Br J Clin Pharmacol 2008; 65: 3-11.
    CrossrefPubMedGoogle Scholar
  • 6 Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with haemophilia B during major orthopaedic procedures. Haemophilia 2001; 07: 517-522.
    CrossrefPubMedGoogle Scholar
  • 7 Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-1127.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Hedner U. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. J Thromb Haemost 2006; 04: 2498-2500.
    CrossrefPubMedGoogle Scholar
  • 9 Wolberg AS, Allen GA, Monroe DM. et al. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645-655.
    CrossrefPubMedGoogle Scholar
  • 10 Konkle BA, Ebbesen LS, Erhardtsen E. et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 05: 1904-1913.
    CrossrefPubMedGoogle Scholar
  • 11 Hoots WK, Ebbesen LS, Konkle BA. et al.; Novo-seven (F7HAEM-1505) Investigators. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia 2008; 14: 466-475.
    CrossrefPubMedGoogle Scholar
  • 12 Morfini M, Auerswald G, Kobelt RA. et al. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-507.
    CrossrefPubMedGoogle Scholar